Compare Jones Lang LaSalle Inc (JLL) vs UnitedHealth Group Inc (UNH) Price & Performance

JLL trades at $362.74, up 1.51% today and near its 52-week high, with a bullish technical signal supported by a golden cross. The company reported strong Q2 2026 earnings, beating estimates with EPS of $5.26 versus $4.56 expected, driven by leasing and capital markets growth. Revenue reached $26.12B in 2025, with net income margin improving to 3.64%. Operating cash flow surged to $1.19B in 2025, reflecting robust financial health. Analyst consensus is a Buy with a $391.50 price target, indicating potential upside from current levels.

The outlook for JLL remains positive given consistent earnings beats, revenue growth, and strong cash flow generation. Key opportunities include momentum in advisory services and recurring revenue streams. Risks involve economic sensitivity to real estate cycles and competitive pressures. Institutional interest is solid, with firms like Bank of America increasing holdings. The stock's valuation at a P/E of 17.43 appears reasonable relative to growth prospects, supporting a constructive view for investors seeking exposure to commercial real estate services.

UnitedHealth Group (UNH) trades at $408.74, showing modest daily gains of 0.41% amid a bearish technical signal. The company demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust analyst support (82.7% buy ratings). Recent developments include dividend payments and strategic initiatives to streamline pediatric care authorizations, positioning UNH well in the healthcare sector.

UNH presents a compelling investment case with strong cash flow generation and market leadership, though investors face risks from regulatory scrutiny and margin compression. The stock trades at a discount to analyst consensus target of $476.50, offering potential upside if operational improvements and growth initiatives materialize as projected.